New research - Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social @israelsenm.bsky.social

Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study Phosphatidylethanol is a direct biomarker of alcohol consumption within the past 1–4 weeks, making it a potential tool in the subclassification of pat…

How should we use PEth in SLD care? 🩸🍺

Our study in @lancetgastrohep.bsky.social (n≈3,000) shows:
🔍 39% of MASLD → MetALD/ALD with PEth
⨻ Triangulating self-report + AUDIT-C + PEth = better classification
⚖️ But 40% get no added value → use selectively

www.sciencedirect.com/science/arti...

Screening for advanced steatotic liver disease Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity...

New Review - Screening for advanced steatotic liver disease

www.thelancet.com/journals/lan...

#LiverSky #MedSky @aleksanderkrag.bsky.social

🎉Our new Impact Factor is 7.5!

We are firmly among the top journals in hepatology👏

Thank you to our authors, reviewers & readers!🙏

#LiverSky
@easlnews.bsky.social

New Editorial — Alcohol and health: time for Europe to sober up

www.thelancet.com/journals/lan...

#alcohol #liversky #medsky

📢Our new Impact Factor is 33.0🎉

🥇Ranking number 1 in the Hepatology field🥇

👏Thanks to the Editorial Team, untiring peer reviewers & very innovative authors❕

#LiverSky
@easlnews.bsky.social

✅ How to reach a #consensus in science 🧬: Clinic director Frank Tacke (Charité) trains future #hepatology leaders on the #DelphiMethod, a reliable forecasting method using multiple rounds of questionnaires for an expert panel to reach a mutual agreement.

🗓️ What a fun #workshop at #EASLCongress 2025

🧪 Mads Israelsen (Odense Universitetshospital – Svendborg Sygehus) leads together with Alberto Zanetto the YI #Workshop on How to prepare a #Clinical #Practice #Guideline in Hepatology, offering valuable insights for young investigators.

📅 Presented at the #EASLCongress | #EASL2025

One last time #LIVE from the #EASLStudio: Tot Ziens Amsterdam, Hola Barcelona! 👋

As #EASL2025 draws to a close, Debbie Shawcross and Aleksander Krag reflect on the highlights from Amsterdam and set the stage for #EASL2026 in Barcelona.

Thank you for an inspiring #EASLCongress - see you next year!

🤩 Full house at General Session 1 today 🥳

Abstract Session “General #Hepatology”, chaired by Aleksander Krag from Odense University Hospital in Denmark 🇩🇰, featuring a broad range of cutting-edge #LiverResearch 🔬.

📅 Presented at #EASLCongress | #EASL2025

🕥 10:30 – 12:30 h

@easlnews.bsky.social

📚 Learning from the best at the EASL Congress: Maja Thiele (OUH) discusses Alcohol-related liver disease as part of The JHEP Reports Symposium: Keys to get your manuscript accepted. 💡
#EASL2025

🐭 Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease

#POSTER THU-058-YI by Maximilian Brol (UM) presents preclinical data showing that blocking MFAP4 reduces #liver #fibrosis in two murine models.

#EASL2025

The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.

In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky

Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion …

🚨New paper from us in Journal of Hepatology - Using PEth values on >50,000 persons to predict outcomes. www.sciencedirect.com/science/arti...

@aleksanderkrag.bsky.social

Fig. 4: The bidirectional linking of factors that predispose to steatotic liver disease.

APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol"

www.nature.com/articles/s41...

#Liversky

@aga-cgh.bsky.social
@majathiele.bsky.social
@aleksanderkrag.bsky.social

#Thorhauge

@aga-cgh.bsky.social
@majathiele.bsky.social
@aleksanderkrag.bsky.social

#Thorhauge

Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments Steatotic liver disease (SLD) includes the subclasses metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD) and alcohol-related liver d...

Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️

Over 60% with MetALD/ALD and 38% with MASLD change subclass.

This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐

Link: www.cghjournal.org/article/S154...

#liversky #gastrosky #oncsky

MASLD vs MetALD/ALD is often reduced to ‘alcohol or not’.

But alcohol use is not binary—and SLD is a dynamic spectrum where alcohol plays a significant role across phenotypes.

Time to rethink the simplistic divide 🧐

@aleksanderkrag.bsky.social
@natrevgastrohep.bsky.social

Have you secured your spot for #EASLCongress 2025 on 7-10 May?

🌍Join us in Amsterdam or online to transform liver care worldwide! easlcongress.eu/2025-registr...
📜The deadline to submit your late-breaker abstract is TODAY, 17 March! easlcongress.eu/2025-abstrac...

New Review - Neurath, Artis, Becker - The intestinal barrier: a pivotal role in health, inflammation, and cancer

www.thelancet.com/journals/lan...

#GastroSky #MedSky

AASLD is here

@aasldnews.bsky.social
@aasldfoundation.bsky.social

#liversky

We're once again hosting the Human #Microbiome conference at @embl.org, organized by Ami Bhatt, Nicola Segata, Mani Arumugam and Peer Bork! We always have a great lineup of speakers, so register now and think about an abstract to submit (abstract submission deadline in June)

Journal of Hepatology is now on Bluesky 🌤️

📢Check our January issue❗️

🎉Celebrating 40 years of discovery in #liverresearch🎉

🙏Thank you to our authors, editors, reviewers, & readers for supporting us on this incredible journey

Full issue here👉https://bit.ly/42en2Kp

#LiverSky
@easlnews.bsky.social

🚀 Join #EASLCongress 2025 (7–10 May, Amsterdam & online) for cutting-edge hepatology, expert insights & hands-on training!

Register Now 👉 easlcongress.eu/2025-registr...
Scientific Programme 👉https://www.easlcongress.eu/2025-scientific-programme/

🚀 7th GA #Meeting in Cologne, Germany from 27-29 January 2025! A huge thank you to everyone for sharing their latest results and project updates! 👏
And of course, we wrapped it up with some after-work fun, exploring Cologne with a @sciencerallye.bsky.social! 🏙️ ⛲

Non-invasive assessment of portal hypertension: Liver stiffness and beyond Portal hypertension (PH) leads to life-threatening clinical manifestations such as bleeding from gastro-oesophageal varices, ascites and its complications, and portosystemic encephalopathy. It can dev...

Happy to share a new review article in JHep Reports written by @mattiasmandorfer.bsky.social @juanabraldes.bsky.social and myself - take a look! www.jhep-reports.eu/article/S258...